Metsera Inc (MTSR) - News Archive

Pfizer s Strategic Acquisition of Metsera Receives Green Light from U.S. Federal Trade Commission Pfizer Inc. (NYSE: PFE) is poised to expand its pharmaceutical portfolio following the U.S. Federal Trade Commission’s (F...

In a significant development poised to influence the landscape of obesity and metabolic disease treatment, Metsera, Inc. (Nasdaq: MTSR) is set to present its pioneering research at the 61st Annual Meeting of the Europea...

Outline of Facts:1. Company Overview: - Metsera, Inc. is a clinical-stage biotechnology company focused on developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides aimed at treat...

Metsera, Inc. Launches Initial Public Offering Priced at $18.00 Per Share, Set to Revolutionize Obesity Treatment MarketOn January 30, 2025, Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biotechnology company specializ...